AI English summary of an SEC filing — figures as filed

The company said first-quarter 2024 reported sales rose 2.3% to $21.4 billion, EPS was $2.20, and adjusted EPS was $2.71, up 12.4%.

8-KResults of Operations and Financial ConditionFiled Apr 16, 2024Period of report Apr 16, 2024Summary published (UTC) Oct 21, 2026

Key points

AI summary

The company said first-quarter 2024 reported sales rose 2.3% to $21.4 billion, EPS was $2.20, and adjusted EPS was $2.71, up 12.4%.
The company said first-quarter operational growth was 3.9% in 2024, with adjusted operational growth at 4.0%, and adjusted operational growth excluding the COVID-19 Vaccine at 7.7%.
The company said Innovative Medicine worldwide operational sales excluding the COVID-19 Vaccine grew 8.3%, or 2.5% including it. MedTech worldwide operational sales grew 6.3%.
The company said it raised its quarterly dividend by 4.2%, from $1.19 to $1.24 per share. It also set its full-year COVID-19 Vaccine-excluded operational sales outlook at $88.7B to $89.1B, compared with $88.2B to $89.0B in January 2024.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q1 2024 Sales and Earnings per Share

The company said first-quarter 2024 reported sales rose 2.3% to $21.4 billion, EPS was $2.20, and adjusted EPS was $2.71, up 12.4%.

Source · Based on the filing body and exhibits

Adjusted Operational Growth and Figures Excluding the COVID-19 Vaccine

The company said first-quarter operational growth was 3.9% in 2024, with adjusted operational growth at 4.0%, and adjusted operational growth excluding the COVID-19 Vaccine at 7.7%.

Source · Based on the filing body and exhibits

Innovative Medicine and MedTech Segment Operational Sales Growth

The company said Innovative Medicine worldwide operational sales excluding the COVID-19 Vaccine grew 8.3%, or 2.5% including it. MedTech worldwide operational sales grew 6.3%.

Source · Based on the filing body and exhibits

Dividend Increase and 2024 Full-Year Outlook

The company said it raised its quarterly dividend by 4.2%, from $1.19 to $1.24 per share. It also set its full-year COVID-19 Vaccine-excluded operational sales outlook at $88.7B to $89.1B, compared with $88.2B to $89.0B in January 2024.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.